Investigation of Matrix Metalloproteinase-2 and 9 in Patients with Chronic Renal Failure

Authors

Hala Basil Abdulameer Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq https://orcid.org/0009-0003-4955-0230
May Khaleel Ismael Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0001-7662-8038

DOI:

https://doi.org/10.30526/38.4.3608

Keywords:

CRF, MMPs, ELISA, detection

Abstract

The family of zinc-dependent endopeptidases known as matrix metalloproteinases (MMPs) has been linked to both healthy and unhealthy kidney physiology. Members of the MMP family known as gelatinases (MMP-2, MMP-9) are essential for the degradation of the extracellular matrix (ECM). This effect plays a significant role in the progression of chronic kidney disease (CKD).and as an indicator of chronic renal failure (CRF), which is a permanent loss of kidney function that occurs when the glomerular filtration rate (GFR) falls below 60 ml/min/1.73 m² for more than 3 months. The presented study was established to investigate the MMP-2 and -9 concentrations in the urine and serum among Iraqi patients with CRF undergoing regular weekly dialysis at the Hamida Al-Misfaa dialysis center of Al-Kadhimiyah Educational Hospital as well as the dialysis center of AL Yarmouk Hospital in Baghdad between November 2022 and January 2023. Detection was done using the sandwich enzyme-linked immunosorbent assay technique. The results indicated that MMP-2 and MMP-9 expression levels in both serum and urine were considerably higher in-patient groups compared to healthy individuals

Author Biographies

Hala Basil Abdulameer, Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq

Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq
May Khaleel Ismael, Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq

Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq

References

1. Khan S, Iqbal S, Khan MN, Khan MN. Left ventricular hypertrophy among non diabetics pre dialysis patients with chronic kidney disease in local population. Res Health Benefits Coconut. 2021; 32:76. https://doi.org/10.1053/j.ajkd.2005.04.031.

2. Kuravatti S, David MP, Indira A. Oral manifestations of chronic kidney disease—an overview. Int J Contemp Med Res. 2016; 3:1149–1152. http://www.ijcmr.com/uploads/7/7/4/6/77464738/_oral_manifestations_of_chronic_kidney_disease-an_overview_.pdf.

3. Alobaidi S. Knowledge of chronic kidney disease among the population of Saudi Arabia evaluated using a validated questionnaire: a cross-sectional study. Patient Prefer Adher.2021;15:1281–1288. https://doi.org/10.2147/PPA.S315369.

4. Jawad A, Al Mulla A, Zardlekawee AS. Levels of trace and essential elements in sera of chronic renal failure patients before and after dialysis. Ibn Al Haitham J Pure Appl Sci. 2009; 22(4):1-8. https://jih.uobaghdad.edu.iq/index.php/j/article/view/1133.

5. Izhar U, Ullah A, Rehman N, Khan KU, Ziaullah MSS. Frequency of hepatitis C virus in chronic kidney disease patients on regular hemodialysis at tertiary care hospital. 2021. https://doi.org/10.53350/pjmhs2115123909

6. Khan AZ, Alam SA, Mahmood MBUR, Khan RA, Ikram T. The frequency of infections of arteriovenous fistula in patients on dialysis with chronic kidney disease. J Med Sci. 2016; 24:224–227.

7. Fernandez Patron C, Kassiri Z, Leung D. Modulation of systemic metabolism by MMP 2: from MMP 2 deficiency in mice to MMP 2 deficiency in patients. Compr Physiol. 2016; 6:1935–1949. https://doi.org/10.1002/cphy.c160010.

8. Shimoda M. Extracellular vesicle associated MMPs: A modulator of the tissue microenvironment. Adv Clin Chem. 2019; 88:35-66. https://doi.org/10.1016/bs.acc.2018.10.006.

9. Parrish AR. Matrix metalloproteinases in kidney disease: role in pathogenesis and potential as a therapeutic target. Prog Mol Biol Transl Sci. 2017; 148:31–65. https://doi.org/10.1016/bs.pmbts.2017.03.001.

10. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012;302: F1351–F1361. https://doi.org/10.1152/ajprenal.00037.2012.

11. Cheng Z, Limbu MH, Wang Z, Liu J, Liu L, Zhang X, Chen P, Liu B. MMP 2 and 9 in chronic kidney disease. Int J Mol Sci. 2017; 18:776. https://doi.org/10.3390/ijms18040776.

12. Björklund M, Koivunen E. Gelatinase mediated migration and invasion of cancer cells. Biochim Biophys Acta Rev Cancer. 2005; 1755:37–69. https://doi.org/10.1016/j.bbcan.2005.03.001.

13. SAS. Statistical Analysis System, User’s Guide. Version 9.6, 6th ed. Cary, NC: SAS Institute Inc.; 2018.

14. Chevalier RL. Bioenergetic evolution explains prevalence of low nephron number at birth: risk factor for CKD. Kidney360. 2020; 1:863. https://doi.org/10.34067/KID.0002012020

15. Goyal S, Arshi SJ, Agarwal B, Rao P, Chauhan S, Haritwal A. An observational study of epidemiological factors among acute and chronic renal failure patients in Gujarat. Eur J Mol Clin Med. 2022; 9(1):359.

16. Rizvi SMMH. Muhit MDM, Tao S, Kalam A, Rahman L, Alom K, Islam S, Rahman A, Jomaddaer M, Hossain Z, Chaity HBS. Treatment and prevention of chronic kidney disease. North Am Acad Res 2023; 6(1): 186-219. https://doi.org/10.5281/zenodo.7622530.

17. Garcia Fernandez N, Jacobs Cachá C, Mora Gutiérrez JM, Vergara A, Orbe J, Soler MJ. Matrix metalloproteinases in diabetic kidney disease. J Clin Med. 2020; 9:472. https://doi.org/10.3390/jcm9020472.

18. Kostov K, Blazhev A. Elevated IgG and IgM autoantibodies to advanced glycation end products of vascular elastin in hypertensive patients with type 2 diabetes: relevance to disease initiation and progression. Pathophysiology. 2022; 29:426–434. https://doi.org/10.3390/pathophysiology29030034.

19. Kuksal A, Kunder M, Balakrishna S. Effect of α1 AT on VEGF and MMP 2 in HUVECs exposed to high glucose and hypoxia: a possible therapeutic approach towards diabetic retinopathy. Romanian J Diabetes Nutr Metab Dis. 2022; 29:310–315. https://www.rjdnmd.org/index.php/RJDNMD/article/view/1102.

20. Al Alawi I, Al Salmi I, Al Mawali A, Al Maimani Y, Sayer JA. End stage kidney failure in Oman: an analysis of registry data with an emphasis on congenital and inherited renal diseases. Int J Nephrol. 2017;2017. https://doi.org/10.1155/2017/6403985.

21. Kuriyama S. A potential mechanism of cardio renal protection with sodium glucose cotransporter 2 inhibitors: amelioration of renal congestion. Kidney Blood Press Res. 2019; 44:449–456. https://doi.org/10.1159/000501081.

22. Low S, Pek S, Liu YL, Moh A, Ang K, Tang WE, Lim Z, Subramaniam T, Sum CF, Lim CL. Higher extracellular water to total body water ratio was associated with chronic kidney disease progression in type 2 diabetes. J Diabetes Complications. 2021; 35:107930. https://doi.org/10.1016/j.jdiacomp.2021.107930.

23. Altemtam N, El Nahas M, Johnson T. Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression. Nephron Extra. 2012; 2:219–232. https://doi.org/10.1159/000339645.

24. Asgari R, Vaisi Raygani A, Aleagha MSE, Mohammadi P, Bakhtiari M, Arghiani N. CD147 and MMPs as key factors in physiological and pathological processes. Biomed Pharmacother. 2023; 157:113983. https://doi.org/10.1016/j.biopha.2022.113983

25. Xu X, Jackson PL, Tanner S, Hardison MT, Abdul Roda M, Blalock JE, Gaggar A. A self propagating matrix metalloprotease 9 (MMP 9) dependent cycle of chronic neutrophilic inflammation. PLoS One. 2011; 6: e15781. https://doi.org/10.1371/journal.pone.0015781

26. Ambade AS, Hassoun PM, Damico RL. Basement membrane extracellular matrix proteins in pulmonary vascular and right ventricular remodeling in pulmonary hypertension. Am J Respir Cell Mol Biol. 2021; 65:245–258. https://doi.org/10.1165/rcmb.2021-0091tr.

27. Musiała A, Donizy P, Augustyniak Bartosik H, Jakuszko K, Banasik M, Kościelska Kasprzak K, Krajewska M, Kamińska D. Biomarkers in primary focal segmental glomerulosclerosis in optimal diagnostic therapeutic strategy. J Clin Med. 2022; 11:3292. https://doi.org/10.3390/jcm11123292

28. Poulsen CG, Rasmussen DG, Genovese F, Hansen TW, Nielsen SH, Reinhard H, von Scholten BJ, Jacobsen PK, Parving H H, Karsdal MA. Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria. PLoS One.2023; 18: e0283296. https://doi.org/10.1371/journal.pone.0283296

29. Ntrinias T, Papasotiriou M, Balta L, Kalavrizioti D, Vamvakas S, Papachristou E, Goumenos DS. Biomarkers in progressive chronic kidney disease. Still a long way to go. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2019;40(3):27-39. https://doi.org/10.2478/prilozi-2020-0002.

30. Hugo A, Rodrigues T, Mader JK, Knoll W, Bouchiat V, Boukherroub R, Szunerits S. Matrix metalloproteinase sensing in wound fluids: are graphene based field effect transistors a viable alternative? Biosens Bioelectron X. 2023; 13:100305. https://doi.org/10.1016/j.biosx.2023.100305.

31. Bieniaś B, Sikora P. Urinary metalloproteinases and tissue inhibitors of metalloproteinases as potential early biomarkers for renal fibrosis in children with nephrotic syndrome. Medicine (Baltimore). 2018;97. https://doi.org/10.5680/lhuii000060.

Downloads

Published

20-Oct-2025

Issue

Vol. 38 No. 4 (2025)

Section

Biology

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

licenseTerms

How to Cite

[1]

Abdulameer, H.B. and Ismael, M.K. 2025. Investigation of Matrix Metalloproteinase-2 and 9 in Patients with Chronic Renal Failure. Ibn AL-Haitham Journal For Pure and Applied Sciences. 38, 4 (Oct. 2025), 10–17. DOI:https://doi.org/10.30526/38.4.3608.